LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular analysis.
Levitas is redefining cellular analytics with its novel platform of magnetic levitation technology. Their disruptive technology overcomes the current technological limitations of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 24, 2022 | Series C | $35M | 1 | — | — | Detail |
Jan 5, 2021 | Series B | $18M | 1 | Thalys Medical Group | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Thalys Medical Group | Yes | Series B |
Pavilion Capital | — | Series C |